RESUMO
INTRODUCTION
Glaucoma is the world's most common blinding condition causing irreversible visual loss (1) . Strong evidence suggests that lowering intraocular pressure (IOP) is beneficial in reducing the development and progression of the disease (2, 3) . Trabeculectomy (TREC) is the surgical procedure of choice to reduce IOP in patients with glaucoma. However, TREC is not 100% successful in maintaining adequate IOP control. A major cause of surgical failure is related to fibroblast proliferation and scarring of the conjunctival bleb (4) (5) (6) . In patients at high risk for failure, adjuvant therapy aiming to inhibit wound healing has been used. 5-fluorouracil (5-FU) or mitomycin C (MMC) have been shown to be effective in increasing TREC success rate (7) (8) (9) (10) (11) (12) (13) , however they have been associated with postoperative complications, such as corneal epithelial defects, wound leak, ischemic bleb, hypotony, blebitis, and endophthalmitis (4, 5) . Beta radiation (BRT) is a particulate radiation consisting of highspeed electrons, which are rapidly attenuated by biological tissues. This makes it very useful for superficial radiation treatments where deep tissue penetration is undesirable. Strontium-90 (90Sr), an unstable fission product of uranium-235 (235U), has been found to be a clinically useful source of beta radiation with a long half-life (28.7 years), and emits only high-energy beta particles as it decays. Among the emitters employed in ophthalmology, the 90Sr source has the most marked attenuation in biological tissues, making it particularly suitable for treatment of the ocular surface.
It has also been used as an auxiliary measure in some ocular procedures, including in pterygium and in age-related macular degeneration (6) (7) (8) (9) (10) (11) . BRT inhibits the proliferation of fibroblasts from the Tenon's capsule and the conjunctiva, both in vitro and in animal models (5) . The effectiveness and safety of adjunct BRT in glaucoma surgery has not been adequately investigated because of small sample size, variable radiation doses and mixed patient groups (6, (14) (15) (16) (17) (18) (19) (20) . Recently a meta-analysis on this issue was published (21) , however in this study the authors did not evaluate the differences on IOP reduction among races, adverse effects as hypotony, hyphema, bleb leak and choroidal effusion. So, we decided to perform a systematic review and metaanalysis in order to analyze the efficacy and safety of TREC followed by beta irradiation (BRT/TREC) compared to TREC alone, including potential differences between distinct ethnic groups.
METHODS
Criteria for considering studies for this systematic review were:
TYPES OF STUDIES
All randomized and quasi-randomized controlled trials were eligible for inclusion.
TYPES OF PARTICIPANTS
Eligibility criteria were: adults with age of 40 years or more, characteristic glaucomatous changes in the optic disc, IOP ≥21 mmHg and open angle on gonioscopy. Trials with participants under 18 years old were not included. There were no restrictions regarding gender or ethnicity.
TYPES OF INTERVENTION
All trials were included when TREC (without adjuvants) was compared to BRT/TREC. All beta radiation emitters contained strontium-90/yttrium-90b (strontium-90 decays to yttrium-90 on release of the beta particle) in 8 mm disc applicator.
TYPES OF OUTCOME MEASURES

Main outcomes
The primary outcome measurement was surgical failure within 12 months, defined as IOP >21 mmHg with antiglaucoma medications. Secondary outcomes were visual acuity, mean IOP reduction, surgical reintervention for cataract, and intraoperative and postoperative complications.
SEARCH STRATEGY FOR STUDIES IDENTIFICATION
The databases on MEDLINE (Ovid) (1996 drainage" (text words) and "adjuvant radiotherapy" (MeSH and text words). These terms were then combined with the search terms for the following study designs: practice guidelines, systematic reviews or meta-analyses, reviews, randomized controlled trials and controlled clinical trials. References of all retrieved studies and reviews were searched for additional trials. Manual searches in ophthalmology, journals or conference proceedings were not undertaken. We did not contact pharmaceutical companies or manufacturers of ophthalmic lasers and surgical equipment.
Two authors independently viewed the titles and abstracts of all the studies identified in the electronic searches. All methodological steps followed the guidelines set by QUOROM statement criteria (22) . The full copies of all possibly or definitely relevant studies were obtained and independently inspected by two authors to determine whether they met the inclusion criteria. When a difference in opinion occurred, a third reviewer was consulted, as an arbiter. The authors of the selected studies could be contacted to elucidate any doubts, when necessary.
DATA ANALYSIS
Studies were examined as to whether the unit of randomization was eyes or people. In all three included studies, the unit of randomization was one eye per patient. Whenever possible, data were extracted on the basis of an intention to treat analysis. Outcomes were analyzed, when possible, in a stratified manner according to short, medium and long-term outcome assessment. One author entered the data into comprehensive meta-analysis and a second author re-entered the data using the double-entry facility to check errors and inconsistencies. IOP was analyzed as a continuous variable. For each study, the mean IOP change from baseline, including the standard deviation (SD) of change for each intervention group, was calculated when possible. If the SD of change was not reported, it was calculated assuming a correlation of 0.5 between the baseline and end-point IOPs (23) . When visual field and visual acuity outcomes were reported as mean scores, data were analyzed as mean score change from baseline and the SD of change. Visual field progression and visual acuity were analyzed when possible as categorical variables. If reported as a score, the data were analyzed as continuous variables. If summary effect measures were reported, the logarithm of the odds ratio (Ln OR) and the standard error (SE) were entered into comprehensive meta-analysis as generic inverse variance measures. When other studies presented similar outcomes using proportions, the OR and the 95% confidence interval (95% CI) were calculated. All meta-analyses were assessed for heterogeneity as a preliminary test. A random-effects model was used if the test of heterogeneity was significant (P<0.05), otherwise a fixedeffects model was used. An OR with a P value <0.05 was considered statistically significant. Publication bias was assessed with the Begg funnel plot and Egger weighted regression for funnel plot asymmetry. Publication bias was considered significant if the Egger test was significant (P<0.05) and the Begg plot suggested bias (24) (25) (26) . Our statistical analysis was performed with comprehensive metaanalysis software (Comprehensive Meta-analysis Version 2; Biostat, Inc. Englewood NJ, 2005).
RESULTS
The electronic and manual searches retrieved 1,350 citations. All citations were screened and 38 full text articles were retrieved for further assessment. Reasons to withdraw the unselected studies included: no randomization, no valid data, absent of control group, review works, etc. Five studies were excluded (18) (19) (20) , since they were either not randomized, controlled or were comparisons of medical versus surgical treatment. The reasons for exclusion are detailed in the figure 1. Three randomized trials met the criteria for inclusion (15) (16) (17) .
No newer study could be considered during the last search performed in January 2011. A summary of the characteristics of the included studies is displayed in table 1.
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SETTING AND PARTICIPANTS
The three selected studies (15) (16) (17) included trials with a total of 457 randomized participants. All participants had newly diagnosed open-angle glaucoma with no prior surgical treatment.
MAIN OUTCOMES
The primary outcome measure in all the trials was the rate of failure to maintain the IOP <21 mmHg at 12 months. Two trials assessed change in visual acuity during the follow-up. Cataract surgery was reported in two trials (16, 17) and additional glaucoma surgery, as a consequence of failure, was reported by all studies. Adverse events were observed in the intervention group in all trials. As the description of these adverse effects was different in each trial, we analyzed each complication separately (Table 2 ).
SURGICAL FAILURE
The three studies reported IOP maintained <21 mmHg at 12 months follow-up as one of the outcomes. Surgical failure rates were lower for the BRT/TREC arm (9/239 = 3.8%) compared to control arms (38/218 =17.4%). The individual odds ratios ranged from 2.97 to 9.29, with a pooled odds ratio for all of the trials of 6.7 with a 95% CI of 3.2 to 14.3 ( Figure 2 ). Since the heterogeneity test showed no statistical significance (P=0.47), the pooling of the data was considered valid. Ethnic subgroups analysis displayed a tendency towards less surgical failure, but not significantly, in the BRT/TREC arm comparing to control arm, in Caucasian patients (P=0.055) (Figure 3 ).
IOP REDUCTION
At 12 months, the BRT/TREC group was associated with significantly greater IOP reduction than TREC alone (difference in the IOP reduction from baseline of 1.65 between groups, 95% CI: 0.61 -2.68), as demonstrated in figure 4 . The subgroups' analysis according to ethnic group revealed that the IOP reduction was greater in Black patients than Caucasian patients in BRT/TREC arm. Black patients showed significant mean difference in the IOP from baseline (2.0 mmHg; 95% CI: 0.6 -3.3, p=0.005), while Caucasian patients presented no significant mean difference (1.2 mmHg; 95% CI: 0.32 -2.8, P=0.120) ( Figure 5 ).
POSTOPERATIVE COMPLICATIONS
All three studies reported postoperative adverse events as one of the outcomes. No complication was described repeatedly in all of these studies. Thus, each complication was analyzed when described in more than one study. Endophthalmitis, uveitis and suprachoroidal hemorrhage were reported in only one of these studies (Table 2 ). No significant difference in the proportion of each There was no significant difference in visual acuity reduction (OR=0.84, 95% CI: 0.5 -1.3, P=0.43) between the two arms. Moreover, no decrease in visual acuity was observed in either group during the study period.
The BRT/TREC group experienced a higher incidence of cataract considering the need for extraction than did the TREC group (25/195 -12 .8% versus 9/190 -4.7% participants), however this difference was not statistically significant (OR=1.85, 95% CI: 0.82 -4.16, P=0.13).
DISCUSSION
The use of BRT in glaucoma surgery has been investigated by several authors (6, (14) (15) (16) (17) (18) (19) (20) but all reports included small numbers of patients, and the irradiation tended to be used in mixed groups of patients with poor prognosis. There are no convincing data from these studies indicating that BRT improves the IOP control posttrabeculectomy, which explains why this technique has not gained popularity.
In our study, combining the results of three randomized trials (457 patients), we were able to demonstrate a significant positive adjunctive effect of BRT in eyes undergoing TREC. The mean difference between the IOP reduction from baseline obtained in BRT-treated eyes and the control group at one year follow-up was 1.64 mmHg (P=0.002).
We did not find any significant difference in the analysis of each complication regarding radiotherapy adjunctive treatment. However, the radiation group experienced a higher incidence of cataract requiring extraction than did the control group (12.8% versus 4.7% respectively; P=0.13). We are not aware if this difference would be significant with an increment of sample size.
The calculated amount of radiation reaching the germinal epithelium of lenses in all trials was probably less than the minimum dosage reported to cause cataract (200 cGy) (27, 28) . Radiation-induced cataract has a characteristic pattern of cortical opacity, starting at the site of application (29) , which was not observed in the patients of those studies.
A possible limitation of the present study could be related to differences in the clinical characteristics of patients included in the groups. Although Rehman et al. (15) and Barnes et al. (16) have compared basically patients on maximal tolerated medical therapy, Kirwan et al. (17) performed surgeries in both patients on maximal therapy and those without previous treatment (Table 1) . These details could explain differences in the surgical results and represent a potential heterogeneity, however a division in subgroups for statistical purposes could be also a source of bias. Moreover, this analysis was not possible due to the lack of detailed data (17) (Table 3 ). The application of beta radiation is rapid and focal, both dose and the area treated can be controlled with accuracy, which reduces the risk of accidental over dosage. A customized applicator is applied only to the desired area. Despite of these advantages of beta radiation, most of glaucoma surgeons choose not to use this procedure probably because the severe adverse events observed in the postoperative period of adjuvant BRT in pterygium surgery. However, we believe that the benefits and complications of the ocular use of beta radiation are open to debate and further studies are necessary.
A previous systematic review has shown similar results (21) , however it was based on an extra study, which is not a RCT and has not been completely published yet (30) . In our analysis, a significant IOP reduction was observed in Black patients (P=0.005), however there is only a trend towards a significant difference for the IOP control in the Caucasian patients treated by BRT (P=0.05). Although Black patients have shown an aggressive healing response (31) , this difference could be explained by sample size of these trials, instead of a real difference due to ethnic subgroups. The necessary statistic power for these two studies (15, 16) able to detect a 10% (postulated) difference in the primary outcome, considering the confidence intervals of 95%, was around 20-25%. In this way, the small number of participants in these studies may compromise the presented statistical analysis. For example, in order to detect a 10% reduction in TREC failure, more than 250 surgeries would be required. Thus, further RCT with an enough sample size should be performed to evaluate the benefits of the BRT in Caucasian patients.
CONCLUSIONS
Our data suggest a significant impact on the outcomes of TREC followed by BRT, mainly in Black patients. Perioperative application of a single dose of BRT in the surgical site showed to be safe, with no significant differences in the frequency of complication, at 12 months follow-up. Further studies are required to assess the impact of BRT in TREC and to determine whether increasing dosage and/or fractionating treatment could enhance the success of routine TREC. Thus, these presented data might be used to guide further randomized clinical trial comparing MMC or 5-FU with adjuvant BRT in glaucoma patients.
